Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins

被引:0
|
作者
K E Tagscherer
A Fassl
B Campos
M Farhadi
A Kraemer
B C Böck
S Macher-Goeppinger
B Radlwimmer
O D Wiestler
C Herold-Mende
W Roth
机构
[1] Molecular Neuro-Oncology,Division of Neurosurgical Research, Department of Neurosurgery
[2] German Cancer Research Center,Division of Molecular Genetics
[3] University of Heidelberg,undefined
[4] Institute of Pathology,undefined
[5] University of Heidelberg,undefined
[6] German Cancer Research Center,undefined
来源
Oncogene | 2008年 / 27卷
关键词
apoptosis; brain tumors; glioma; ABT-737; Bcl-2 inhibitor;
D O I
暂无
中图分类号
学科分类号
摘要
Defects in the apoptotic signaling cascades contribute to the poor therapeutic response of malignant gliomas. As glioblastomas are characterized by high expression levels of anti-apoptotic Bcl-2 family proteins, we studied the effects of the novel Bcl-2 inhibitor, ABT-737, on malignant glioma cells. ABT-737 treatment released the pro-apoptotic Bax protein from its binding partner Bcl-2 and potently induced apoptotic cell death in glioblastoma cells in vitro and in vivo. The local administration of ABT-737 prolonged the survival in an intracranial glioma xenograft model. Downregulation of Mcl-1 and overexpression of Bcl-2 sensitized the cells to ABT-737-mediated apoptosis. Moreover, ABT-737 potentiated the cytotoxicity of the chemotherapeutic drugs vincristine and etoposide, and of the death ligand TRAIL. As glioma stem cells may play a crucial role for the tumor progression and the resistance to treatment in glioblastomas, we investigated the effects of ABT-737 on the subpopulation of glioma cells exhibiting stem cell characteristics. Inhibition of proliferation and induction of apoptosis by ABT-737 were less efficient in glioma stem cells than in non-stem cell-like glioma cells. As the resistance of glioma stem cells was associated with high Mcl-1 expression levels, ABT-737 treatment combined with downregulation of Mcl-1 could represent a promising novel approach in glioblastoma treatment.
引用
收藏
页码:6646 / 6656
页数:10
相关论文
共 50 条
  • [41] BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia
    Moore, Victoria Del Gaizo
    Schlis, Krysta D.
    Sallan, Stephen E.
    Armstrong, Scott A.
    Letai, Anthony
    BLOOD, 2008, 111 (04) : 2300 - 2309
  • [42] Inhibition of Bcl-2 signaling at nanomolar concentrations by small molecule BH3 inhibitor, ABT-737 as a novel therapeutic strategy in acute myeloid leukemia (AML).
    Contractor, R
    Konopleva, M
    Deng, XM
    Harris, D
    Ruvolo, P
    Estrov, Z
    May, WS
    Rosenberg, SH
    Andreeff, M
    BLOOD, 2004, 104 (11) : 217A - 218A
  • [43] Inducing apoptosis in mantle cell lymphoma using inhibitors of cyclin-dependent kinases and the Bcl-2 inhibitor ABT-737
    Lo, Wann-Cheng
    LeBrun, David P.
    Greer, Peter A.
    CANCER RESEARCH, 2012, 72
  • [44] Targeting Bcl-2 Family Proteins in Adult T-Cell Leukemia/Lymphoma: In Vitro and In Vivo Effects of a Novel Bcl-2 Family Inhibitor ABT-737.
    Ishitsuka, Kenji
    Ishikawa, Chie
    Yotsumoto, Fusanori
    Katsuya, Hiroo
    Kunami, Naoko
    Sawada, Shigeki
    Tanji, Hiroe
    Takeshita, Morishige
    Miyamoto, Shingo
    Mori, Naoki
    Tamura, Kazuo
    BLOOD, 2009, 114 (22) : 672 - 672
  • [45] The BCL-2 family protein inhibitor ABT-737 as an additional tool for the treatment of EBV-associated post-transplant lymphoproliferative disorders
    Robert, Aude
    Pujals, Anais
    Favre, Loetitia
    Debernardi, Justine
    Wiels, Joelle
    MOLECULAR ONCOLOGY, 2020, 14 (10) : 2520 - 2532
  • [46] 'Aerobically poised' leukaemia cells are resistant to the mitochondrial toxin and BCL-2/BCL-XL inhibitor, ABT-737
    Miles, Gareth
    Langlais, Claudia
    MacFarlane, Marion
    Cain, Kelvin
    TOXICOLOGY LETTERS, 2014, 229 : S74 - S74
  • [47] The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan
    Trudel, Suzanne
    Stewart, A. Keith
    Li, Zhihua
    Shu, Yanjun
    Liang, Sheng-Ben
    Trieu, Young
    Reece, Donna
    Paterson, Josh
    Wang, Dingyan
    Wen, Xiao-Yan
    CLINICAL CANCER RESEARCH, 2007, 13 (02) : 621 - 629
  • [48] An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737
    Al-Harbi, Sayer
    Hill, Brian T.
    Mazumder, Suparna
    Singh, Kamini
    DeVecchio, Jennifer
    Choudhary, Gaurav
    Rybicki, Lisa A.
    Kalaycio, Matt
    Maciejewski, Jaroslaw P.
    Houghton, Janet A.
    Almasan, Alexandru
    BLOOD, 2011, 118 (13) : 3579 - 3590
  • [49] The Synergistic Effect of DNA Methylation Inhibitor 5-Azacytidine and Bcl-2 Signaling Blockade ABT-737 Combination Treatment Induce Apoptosis In AML
    Shi, Yuexi
    Tsao, Twee
    Lu, Hongbo
    Konoplev, Sergej
    Schober, Wendy D.
    Andreeff, Michael
    Konopleva, Marina
    BLOOD, 2010, 116 (21) : 1356 - 1357
  • [50] Pro-apoptotic activity of the BCL-2 inhibitor ABT-737 on primary multiple myeloma samples
    Ricciardi, M. R.
    Gregorj, C.
    De Cave, F.
    Calabrese, E.
    Santinelli, S.
    Federico, V.
    Bergamo, P.
    Milella, M.
    Foa, R.
    Tafuri, A.
    Petrucci, M. T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 145 - 145